Transgene Biotek Financial Statements

Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar Mar-2020 Mar-2018 Mar-2017 Mar-2016
Growth matrix (%)        
Revenue growth (97) (58) 54.70 (42)
Op profit growth (59) (18) 126 (30)
EBIT growth 129 (76) (9.50) 14.40
Net profit growth 70.30 (68) (7.80) 12.60
Profitability ratios (%)        
OPM (24,156) (1,781) (912) (623)
EBIT margin (295,958) (3,911) (6,919) (11,824)
Net profit margin (306,602) (5,445) (7,072) (11,864)
RoCE (20) (6.70) (15) (11)
RoNW (6.40) (2.90) (4.30) (2.90)
RoA (5.20) (2.30) (3.80) (2.70)
Per share ratios ()        
EPS -- -- -- --
Dividend per share -- -- -- --
Cash EPS (2.80) (2.20) (4.90) (5.50)
Book value per share 4.31 6.92 7.77 23
Valuation ratios        
P/E -- -- -- --
P/CEPS (1.10) (1) (0.40) (0.30)
P/B 0.70 0.30 0.23 0.08
EV/EBIDTA (48) 4.86 (16) (30)
Payout (%)        
Dividend payout -- -- -- --
Tax payout -- 13.90 -- --
Liquidity ratios        
Debtor days 1,021 30.90 1,072 18,136
Inventory days 4,083 170 91 141
Creditor days (196) (89) (89) (2,285)
Leverage ratios        
Interest coverage 27.80 4.50 45.20 294
Net debt / equity 0.31 0.19 0.27 0.09
Net debt / op. profit (12) (4.60) (6.20) (13)
Cost breakup ()        
Material costs (414) (41) -- (0.40)
Employee costs (8,098) (277) (197) (375)
Other costs (15,744) (1,562) (815) (347)
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar( In .Cr) Mar-2020 Mar-2018 Mar-2017 Mar-2016
Revenue -- 0.12 0.28 0.18
yoy growth (%) (97) (58) 54.70 (42)
Raw materials -- -- -- --
As % of sales 414 41.20 -- 0.41
Employee costs (0.30) (0.30) (0.60) (0.70)
As % of sales 8,098 277 197 375
Other costs (0.60) (1.80) (2.30) (0.60)
As % of sales 15,744 1,562 815 347
Operating profit (0.90) (2.10) (2.60) (1.10)
OPM (24,156) (1,781) (912) (623)
Depreciation (9.90) (9.90) (18) (21)
Interest expense (0.40) (1) (0.40) (0.10)
Other income 0.18 7.37 0.66 0.17
Profit before tax (11) (5.70) (20) (22)
Taxes -- (0.80) -- --
Tax rate -- 13.90 -- --
Minorities and other -- -- -- --
Adj. profit (11) (6.40) (20) (22)
Exceptional items -- -- -- --
Net profit (11) (6.40) (20) (22)
yoy growth (%) 70.30 (68) (7.80) 12.60
NPM (306,602) (5,445) (7,072) (11,864)
Switch to
Tabular Data
Graph
Y/e 31 Mar ( In .Cr) Mar-2020 Mar-2018 Mar-2017 Mar-2016
Profit before tax (11) (5.70) (20) (22)
Depreciation (9.90) (9.90) (18) (21)
Tax paid -- (0.80) -- --
Working capital (33) (4.30) (2.40) (0.70)
Other operating items -- -- -- --
Operating cashflow (54) (21) (40) (43)
Capital expenditure (7.40) (8.60) (101) --
Free cash flow (61) (29) (141) (43)
Equity raised 178 238 269 250
Investments -- -- -- --
Debt financing/disposal 2.97 17.80 26.60 16.50
Dividends paid -- -- -- --
Other items -- -- -- --
Net in cash 119 227 155 224
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2020 Mar-2019 Mar-2018 Mar-2017
Equity capital 75.80 75.80 75.80 75.80
Preference capital -- -- -- --
Reserves (43) (32) (23) (17)
Net worth 32.70 43.60 52.40 58.90
Minority interest
Debt 10.30 9.14 9.84 16
Deferred tax liabilities (net) -- -- -- --
Total liabilities 43 52.80 62.30 74.90
Fixed assets 33.10 43 52.80 63.20
Intangible assets
Investments -- -- -- --
Deferred tax asset (net) -- -- -- --
Net working capital 9.90 9.70 9.34 11.60
Inventories 0.04 0.03 0.04 0.07
Inventory Days 4,083 -- 123 91
Sundry debtors 0.01 0.01 0.01 0.01
Debtor days 1,021 -- 30.90 13
Other current assets 134 133 134 135
Sundry creditors (0.40) (0.30) (0.60) (0.50)
Creditor days 38,793 -- 1,698 702
Other current liabilities (123) (123) (124) (123)
Cash 0.04 0.10 0.10 0.05
Total assets 43 52.80 62.30 74.90
Switch to
Consolidated
Standalone


Particulars ( Rupees In Crores.) Mar-2020 Mar-2019 Mar-2013 Mar-2012 Mar-2011
Gross Sales -- 0.07 15 26.30 9.97
Excise Duty -- -- -- -- --
Net Sales -- 0.07 15 26.30 9.97
Other Operating Income -- -- -- -- --
Other Income 0.18 2.04 0.06 17.10 0.05
Total Income 0.18 2.11 15.10 43.30 10
Total Expenditure ** 0.87 0.76 15.90 25.10 8.79
PBIDT (0.70) 1.35 (0.80) 18.20 1.23
Interest 0.38 0.25 0.20 0.63 0.71
PBDT (1.10) 1.10 (1) 17.60 0.52
Depreciation 9.90 9.89 1.02 0.38 0.35
Minority Interest Before NP -- -- -- -- --
Tax -- -- -- 5.60 0.03
Deferred Tax -- -- -- -- --
Reported Profit After Tax (11) (8.80) (2) 11.60 0.14
Minority Interest After NP -- -- -- -- --
Net Profit after Minority Interest (11) (8.80) (2) 11.60 0.14
Extra-ordinary Items -- -- -- 9.56 (1.10)
Adjusted Profit After Extra-ordinary item (11) (8.80) (2) 2.04 1.27
EPS (Unit Curr.) (1.50) (1.20) (0.30) 2.19 0.08
Book Value (Unit Curr.) -- -- -- -- --
Dividend (%) -- -- -- -- --
Equity 75.80 75.80 65.80 65.80 40.80
Public Shareholding (Number) -- -- 59,342,096 59,336,096 34,301,860
Public Shareholding (%) -- -- 90.20 90.20 84.10
Pledged/Encumbered - No. of Shares -- -- -- -- 330,500
Pledged/Encumbered - % in Total Promoters Holding -- -- -- -- 5.11
Pledged/Encumbered - % in Total Equity -- -- -- -- 0.81
Non Encumbered - No. of Shares -- -- 6,427,902 6,433,902 6,137,639
Non Encumbered - % in Total Promoters Holding -- -- 100 100 94.90
Non Encumbered - % in Total Equity -- -- 9.78 9.78 15.10
PBIDTM(%) -- 1,929 (5.40) 69.40 12.30
PBDTM(%) -- 1,571 (6.70) 67 5.22
PATM(%) -- (12,557) (14) 44.20 1.40